1 / 6
Laboratory Research Material
Vesugen 20mg
- Compound
- Vesugen
- Amount per vial
- 20 mg
- Form
- Lyophilized powder
- Packaging
- 1 × 3 mL vial, boxed
- Shipping
- FedEx 2DayShips from the U.S. Estimated arrival2 business days after dispatchWeekday dispatch · 4 p.m. ET cutoff
Delivery details
Estimated for in-stock orders using FedEx 2Day. Weekends and FedEx closures are excluded. Holiday pickups, destination and carrier delays can affect arrival. Alaska and Hawaii may take longer.
Free U.S. shipping on orders $199+
Important
Research Use Notice
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Product Documentation
Details, specifications, and reviews
Description
Vesugen 20 mg: research material
Buy Vesugen 20 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp, abbreviated KED. It is investigated in cell-culture models, including experiments on vascular endothelial cells and markers associated with proliferation.
Choose the material and presentation
The selected vial contains a labeled 20 mg of material. Its 3 mL capacity identifies the container size, not a supplied solution volume or concentration.
Sequence order and length distinguish this material from related short peptides. KED is different from KEDG, KEDP and KEDW, each of which contains another amino-acid residue. Compare the complete sequence and supplied chemical form with the material used in your chosen study. Capsules, mixed tissue extracts and formulated solutions are different preparations.
Vesugen in endothelial-cell experiments
In an original vascular-cell study, researchers examined rat tissue explants and cultured aortic endothelial cells. The dissociated cells were compared at early and later culture passages. Ki-67 staining was used as a proliferation-associated readout.
The authors reported increases in Ki-67-positive area with Vesugen in the tested cultures. They also modeled possible interactions with promoter regions of the MKI67 gene. That docking analysis was computational; it did not directly demonstrate peptide-DNA binding inside cells.
The distinction between observation and explanation matters here. A change in a culture marker does not establish improved circulation, vascular repair or an anti-aging effect in people. Nor does a result from the study establish the activity of a particular supplied lot.
Product records and batch reports
Use the COA & Documents tab to review the available reports and product files. Match the compound, presentation and lot before relying on a batch report. Identity results, chromatographic purity and measured material content answer different questions.
Confirm the specifications needed for your laboratory workflow, including supplied chemical form and supported storage or handling conditions. Published biological findings and supplier analytical records serve different purposes; neither should be used as a substitute for the other.
Additional information
| CAS No. | 99469-43-9 |
|---|---|
| Purity | ≥99% |
| Synthesis Method | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Water or validated laboratory buffer |
| Stability & Storage | Up to 24 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Applications | In-vitro assay research, compound characterization, analytical method development |
| Appearance | White to off-white powder |
| Regulatory/Compliance | Not for human consumption. For research use only. |
| Safety Information | MSDS available upon request |
Independent lot testing
Vesugen 20mg Certificate of Analysis
This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.
- Lot number
- 18854
- Report number
- 39801
- Date tested
- September 17, 2026
- Reported purity
- 99.892%
- Labeled content
- 20 mg
Product documents
Product information and laboratory resources. For lot-specific results, use the COA above.
Product & packaging information
Labeled amount, physical form and packaging for Vesugen 20mg.
Revision 0.4 · 2026-10-05Download PDFLaboratory handling guide
General guidance for applicable lyophilized research materials. Not a product-specific SDS.
Revision 1.0 · 2026-09-22Download PDFGeneral guides & resources
Reading a COA & Verifying Your Lot
PDF · Revision 1.0Receiving, Storage & Traceability Record
PDF · Revision 1.0Research Use & Documentation Scope
PDF · Revision 1.0Only logged in customers who have purchased this product may leave a review.
Need Assistance?
Questions about product documentation?
Our support team can assist with product records, lot information, order questions, and certificate verification.

There are no reviews yet.